Leerink Partnrs Issues Pessimistic Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of Thermo Fisher Scientific in a report released on Wednesday, April 23rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $5.23 for the quarter, down from their prior forecast of $5.41. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q3 2025 earnings at $5.41 EPS, Q4 2025 earnings at $6.60 EPS and FY2025 earnings at $22.39 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period in the prior year, the company earned $5.11 EPS. The firm's revenue was up .2% on a year-over-year basis.

Other equities analysts have also recently issued reports about the stock. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a research report on Friday, January 10th. UBS Group reduced their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $616.95.

Thermo Fisher Scientific Stock Down 0.6 %

Thermo Fisher Scientific stock traded down $2.69 during trading on Friday, reaching $421.55. 2,527,222 shares of the company's stock were exchanged, compared to its average volume of 1,746,685. The company's 50-day moving average is $487.28 and its two-hundred day moving average is $526.70. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific has a 52-week low of $409.85 and a 52-week high of $627.88. The firm has a market cap of $159.13 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 2.99 and a beta of 0.86.

Institutional Investors Weigh In On Thermo Fisher Scientific

Large investors have recently modified their holdings of the stock. Nordea Investment Management AB raised its position in shares of Thermo Fisher Scientific by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after purchasing an additional 10,606 shares during the period. S.E.E.D. Planning Group LLC raised its position in shares of Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after purchasing an additional 618 shares during the period. Czech National Bank raised its position in shares of Thermo Fisher Scientific by 6.6% during the fourth quarter. Czech National Bank now owns 82,934 shares of the medical research company's stock worth $43,145,000 after purchasing an additional 5,118 shares during the period. Douglas Lane & Associates LLC raised its position in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company's stock worth $94,948,000 after purchasing an additional 3,460 shares during the period. Finally, Granite Bay Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $4,758,000. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,900 shares of company stock worth $13,106,062. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.